Regulatory agencies and the pharmaceutical industry are currently focusing on the use of Quality by Design (QbD) in the creation of Pharmaceutical products. In its recommendations for the industry, the International Conference on Harmonization and the United States Food and Drug Administration (USFDA) underlined the QbD principles and applications in Pharmaceutical Development. The USFDA established a question-based review process for the chemical, manufacturing, and controls component of abbreviated new drug applications that addresses QbD qualities. When QbD principles are applied, effective product development, rapid regulatory approval, a reduced burden from extensive validation, and a considerable decrease in post-approval adjustments result. To comprehend the performance of dosage forms within design space, the major components of Quality by design—namely, the goal product quality profile, crucial quality attributes, risk assessments, design space, control strategy, product lifecycle management, and ongoing improvement—are examined. Additionally mentioned are the design of experiments, risk assessment techniques, and process analytical technologies. The significance of QbD in fostering a science-based approach in Pharmaceutical Product Development is highlighted by this review.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia